Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

DORA Trial: Phase 3 Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This clinical trial is for men age 18 and older with metastatic castration-resistant prostate cancer (mCRPC), which is prostate cancer that no longer responds to hormone therapy. The cancer spreads (metastasizes) to the bones. 

AGCT1532: Phase 3 Accelerated BEP Trial: A Randomized Phase 3 trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Standard treatment for advanced germ cell tumors includes three chemotherapy drugs called BEP (Bleomycin, Etoposide, and cisPlatin). BEP is given with a drug called pegfilgrastim or filgrastim which makes white blood cells grow. These drugs are given over the course of 3 weeks. Previous research has been done in studying BEP to improve the outcome of patients with poor-risk GCTs. One method that was tried is called dose intensification. This method works by giving the dose of chemotherapy drugs over a shorter length of time.

Pembrolizumab and Stereotactic Radio Surgery (SRS) of Selected Brain Metastases in Breast Cancer Patients

Breast cancer subjects with multiple brain metastases are often initially treated with stereotactic radiosurgery (SRS), a non-surgical radiation technique used to treat small brain tumors or whole brain radiation therapy (WBRT). When initially managed with SRS, subjects often develop new brain metastases in the untreated brain, requiring additional SRS procedures and, eventually, WBRT, which is often associated with significant neurocognitive sequelae (headache, nausea, dizziness, confusion, memory loss and motor dysfunction).

Long term Outcomes of Obese Patients with Gastrointestinal Complications of Disease

This is an observational study for men and women who have a body mass index (BMI) of greater than 30 kg/m2 and have a history of liver or gastrointestinal (GI) problems. 

Our Clinical Trial Locations

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

A Phase 1 Study With an Expansion Cohort/Randomized Phase 2 Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

The purpose of this study is to test the safety of the combination of multiple drugs: brentuximab vedotin which is approved for use in relapsed Hodgkin lymphoma, ipilimumab and nivolumab both drugs which stimulate your immune system, and which are approved for use in other cancers, but are investigational for Hodgkin lymphoma.

JCTO Fees

For inquires, please contact JCTOfinance@med.cornell.edu.

JCTO Fees

Fee Type

Fee Amount

Fee Required

Rationale

JCTO

$5,000

Industry-Sponsored (initiated and funded by industry)

Advanced Endoscopic Therapies (AETs): A Retrospective and Prospective Multicenter Registry

This is an observational study. This study is for men and women who will undergo a standard of care advanced endoscopic therapeutic procedure and subsequent follow‐up clinic visits.